Ara
Toplam kayıt 36, listelenen: 31-36
Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa
(Wiley, 2024)
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed ...
Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: Results from a single-center biopsy study
(Wolters Kluwer Medknow Publications, 2024)
To the Editor: The nomenclature for steatotic liver disease has been a topic of debate since 2020. The conventional expression, non-alcoholic fatty liver disease (NAFLD), was introduced in 1980 to describe the occurrence ...
Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study
(Kare Publishing, 2023)
Background and Aim: Metabolic-associated fatty liver disease (MAFLD) is a condition that frequently goes unnoticed as it typically remains asymptomatic until progressing to an advanced stage. As a result, it is essential ...
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
(Elsevier, 2023)
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient ...
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis
(Wiley, 2024)
Background & Aims: There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4) ...
Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
(Wiley, 2024)
Patients with chronic liver disease (CLD) experience health-related quality of life (HRQoL) and patient-reported outcomes (PROs) impairments. We assessed and identified predictors of HRQoL and PROs in CLD patients from ...